Eli Lilly and Co., of Indianapolis, reported that three Phase III studies of edivoxetine failed to meet the primary objective of superior efficacy in major depressive disorder (MDD) after eight weeks of treatment. When added to a selective serotonin reuptake inhibitor, edivoxetine did not separate from placebo on the Montgomery-Asberg Depression Rating Scale in the acute, randomized, placebo-controlled studies (LNBM, LNBQ and LNBR).